Focusing on Risk Communication About Medicines: Why Now?

di Bahri, Priya, Harrison-Woolrych, Mira
Pubblicazione 2012

Listen to the public and fulfil their information interests – translating vaccine communication research findings into guidance for regulators

di Bahri, Priya, Castillon Melero, Mireia
Pubblicato in Br J Clin Pharmacol (2018)

Application of real-time global media monitoring and ‘derived questions’ for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines

di Bahri, Priya, Fogd, Julianna, Morales, Daniel, Kurz, Xavier
Pubblicato in BMC Med (2017)

Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Sta...

di Bahri, Priya, Morales, Daniel R., Inoubli, Adrien, Dogné, Jean-Michel, Straus, Sabine M. J. M.
Pubblicato in Drug Saf (2020)

The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products

di Smith, Meredith Y., Russell, Andrea, Bahri, Priya, Mol, Peter G. M., Frise, Sarah, Freeman, Emily, Morrato, Elaine H.
Pubblicato in Drug Saf (2017)

Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments

di McGettigan, Patricia, Alonso Olmo, Carla, Plueschke, Kelly, Castillon, Mireia, Nogueras Zondag, Daniel, Bahri, Priya, Kurz, Xavier, Mol, Peter G. M.
Pubblicato in Drug Saf (2019)

Correction to: Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments

di McGettigan, Patricia, Alonso Olmo, Carla, Plueschke, Kelly, Castillon, Mireia, Nogueras Zondag, Daniel, Bahri, Priya, Kurz, Xavier, Mol, Peter G. M.
Pubblicato in Drug Saf (2019)